Elacridar hydrochloride

CAS No. 143851-98-3

Elacridar hydrochloride ( GF-120918A )

Catalog No. M11860 CAS No. 143851-98-3

A potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 292 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Elacridar hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.
  • Description
    A potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM; effectively competes with [3H]azidopine for binding P-glycoprotein; restores sensitivity of the tumor to a single dose of doxorubicin in mice; orally bioavailable.Breast CancervPhase 1 Discontinued
  • Synonyms
    GF-120918A
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    P-glycoprotein
  • Recptor
    P-glycoprotein
  • Research Area
    Cancer
  • Indication
    Breast Cancer

Chemical Information

  • CAS Number
    143851-98-3
  • Formula Weight
    600.10
  • Molecular Formula
    C34H34ClN3O5
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC.Cl
  • Chemical Name
    4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-, hydrochloride (1:1)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Hyafil F, et al. Cancer Res. 1993 Oct 1;53(19):4595-602.
2. den Ouden D, et al. Leukemia. 1996 Dec;10(12):1930-6.
3. Witherspoon SM, et al. Clin Cancer Res. 1996 Jan;2(1):7-12.
molnova catalog
related products
  • Tariquidar methanesu...

    A potent, specific P-gp inhibitor with Kd of 5.1 nM.

  • Valspodar

    A highly potent multidrug-resistance modifier that acts as a P-glycoprotein inhibitor.

  • Dofequidar

    A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR.